FDA Approves Lurbinectedin in Combination with Atezolizumab or Atezolizumab and Hyaluronidase-tqjs for Extensive Stage SCLC By Ogkologos - October 16, 2025 227 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Popular Fitness Instructor Encourages Others to Maintain Routine Check Ups After... February 9, 2021 BREAKING: President Trump May Restore The WHO’s Funding, With Some Conditions May 18, 2020 Her Massive Weight Loss Helped Her Feel A Lump In Her... January 24, 2020 Coverage for Breast Cancer Genetic Marker Testing is Still Being Denied... July 20, 2021 Load more HOT NEWS Breast Cancer Patient Fights To Have Mastectomy During COVID-19 Restrictions And... COVID-19 Vaccination Efficient in Patients with Cancer Who Receive Active Anticancer... Adding Tafasitamab to Lenalidomide and Rituximab Prolongs PFS in Patients with... Immune Checkpoint Inhibitor Induced Thyroiditis Associated with a Large Reduction in...
